CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 36 enrolled
Drug / intervention
Enzalutamidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02099864
NCT02099864Phase 2Completed
CompareCT.gov

Molecular Mechanisms Underlying Tumor Progression Despite Enzalutamide Treatment

OHSU Knight Cancer Institute·interventional·Posted Mar 31, 2014·Updated Sep 19, 2024

In Brief

A Phase 2 clinical trial evaluating Enzalutamide for Castration-Resistant Prostate Carcinoma and 6 related conditions. Completed, enrolled 36 participants across 2 sites.

Detailed Summary

This phase II trial studies genetic and molecular mechanisms in assessing response in patients with prostate cancer receiving enzalutamide therapy. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as enzalutamide, may lessen the amount of androgens made by the body. Studying samples of tissue and blood in the laboratory from patients with prostate cancer may help doctors better understand castration-resistant prostate cancer. It may also help doctors make improvements in prostate cancer treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCastration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage III Prostate Adenocarcinoma AJCC v7, Stage IV Prostate Adenocarcinoma AJCC v7
CountriesUnited States
CollaboratorsAstellas Pharma US, Inc., Oregon Health and Science University

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 31, 2014
Enrollment StartFeb 5, 2014
Primary CompletionOct 1, 2019
Study CompletionJul 8, 2024
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 12.3 years ago

Interventions

Enzalutamidedrug

Given PO